litlas
Log inCreate account

William G. Wierda

Active 1989–2025

318
Papers
56,759
Citations
127
h-index
312
i10-index

Citations

Citations per year for William G. Wierda1979: 1 citations1990: 1 citations1991: 1 citations1992: 2 citations1993: 1 citations1994: 4 citations1995: 1 citations1996: 2 citations1997: 3 citations1998: 2 citations1999: 6 citations2000: 10 citations2001: 11 citations2002: 20 citations2003: 48 citations2004: 53 citations2005: 47 citations2006: 110 citations2007: 155 citations2008: 232 citations2009: 310 citations2010: 352 citations2011: 321 citations2012: 380 citations2013: 378 citations2014: 424 citations2015: 526 citations2016: 465 citations2017: 560 citations2018: 682 citations2019: 1,884 citations2020: 2,367 citations2021: 2,520 citations2022: 1,890 citations2023: 1,380 citations2024: 2,399 citations2025: 1,133 citations2026: 41 citations1980–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,400 citing papers, 29.6% of this breakdownChina: 1,750 citing papers, 9.6% of this breakdownGermany: 1,267 citing papers, 6.9% of this breakdownUnited Kingdom: 1,111 citing papers, 6.1% of this breakdownItaly: 1,078 citing papers, 5.9% of this breakdownFrance: 783 citing papers, 4.3% of this breakdownAustralia: 613 citing papers, 3.3% of this breakdownSpain: 582 citing papers, 3.2% of this breakdownCanada: 458 citing papers, 2.5% of this breakdownNetherlands: 434 citing papers, 2.4% of this breakdownSwitzerland: 379 citing papers, 2.1% of this breakdownSweden: 303 citing papers, 1.7% of this breakdown
0%29.6%Other 22.4%

Institutions

Fields

  • Medicine73.2%
  • Biochemistry, Genetics and Molecular Biology17.1%
  • Immunology and Microbiology6.8%
  • Chemistry0.7%
  • Engineering0.4%
  • Computer Science0.4%
  • Other1.4%

Topics

  • CAR-T cell therapy research9.9%
  • Chronic Lymphocytic Leukemia Research9.5%
  • Lymphoma Diagnosis and Treatment7%
  • Immune Cell Function and Interaction4.2%
  • Acute Myeloid Leukemia Research4.2%
  • Chronic Myeloid Leukemia Treatments3.5%
  • Other61.7%

Coauthors

All papers

Open in search
  1. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    Authors: Enli Liu, David Marín, Pinaki P. Banerjee, Homer A. Macapinlac, Philip A. Thompson, Rafet Başar, Lucila Nassif Kerbauy, Bethany Overman, Peter F. Thall, Mecit Kaplan, Vandana Nandivada, Indresh Kaur, Ana Karen Nunez Cortes, Kai Cao, May Daher, Chitra Hosing, Evan N. Cohen, Partow Kebriaei, Rohtesh S. Mehta, Sattva S. Neelapu, Yago Nieto, Michael Wang, William G. Wierda, Michael J. Keating, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani - New England Journal of Medicine 2020 cited by 2,139

  2. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    Authors: Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Cristina Gutiérrez, Frederick L. Locke, Krishna V. Komanduri, Yi Lin, Nitin Jain, Naval Daver, Jason R. Westin, Alison Gulbis, Monica Loghin, John de Groot, Sherry Adkins, Suzanne E. Davis, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall - Nature Reviews Clinical Oncology 2017 cited by 2,380

  3. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

    Authors: Bijal Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O’Dwyer, Martha Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick J. Stiff, Deepa Jeyakumar, Chaoling Feng, Jinghui Dong, Tong Shen, Francesca Milletti, John M. Rossi, Remus Vezan, Behzad Kharabi Masouleh, Roch Houot - The Lancet 2021 cited by 769

  4. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    Authors: Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, Jennifer R. Brown, Lori A. Gressick, Shekman Wong, Martin Dunbar, Ming Zhu, Monali Desai, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, William G. Wierda, John F. Seymour - New England Journal of Medicine 2015 cited by 1,884

  5. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

    Authors: Reuben Benjamin, Charlotte Graham, Deborah Yallop, Agnieszka Jóźwik, Oana Mirci‐Danicar, Giovanna Lucchini, Danielle Pinner, Nitin Jain, Hagop M. Kantarjian, Nicolas Boissel, Marcela V. Maus, Matthew J. Frigault, André Baruchel, Mohamad Mohty, Athos Gianella-Borradori, Florence Binlich, Svetlana Balandraud, Fabien Vitry, E. W. Prosser Thomas, Anne Philippe, Sylvain Fouliard, Sandra Dupouy, Ibtissam Marchiq, Maria Almena-Carrasco, Nicolas Ferry, Sylvain Arnould, Cyril Konto, Paul Veys, Waseem Qasim, Reuben Benjamin, Charlotte Graham, Deborah Yallop, Agnieszka Jóźwik, Antonio Pagliuca, Ghulam Mufti, Piers Patten, Shireen Kassam, Stephen Devereux, Majid Kazmi, Kirsty Cuthill, Victoria Potter, Andrea Kühnl, Victoria Metaxa, Laarni Bonganay, Orla Stewart, Rose Ellard, Lorraine Catt, Jen Lewis, Farzin Farzaneh, Jackie Chappell, Alice Mason, Vicky Chu, Alan Dunlop, Adeel Saleem, Gary Cheung, Helena Munro, Elka Giemza, Waseem Qasim, Paul Veys, Oana Ciocârlie, Giovanna Lucchini, Danielle Pinner, Jan Chu, Persis Amrolia, Kanchan Rao, Robert Chiesa, Juliana Silva, Annette Hill, Maria Finch, Lindsey Young, Harvinder Hara, Sujith Samarasinghe, Anupama Rao, Ajay Vora, Anupama Rao, Christine Rivat, Clare Murphy, Gulrukh Ahsan, Rasha Said Shamsah, Jesmina James, Sarah Inglott, Gary Wright, Stuart Adams, Natalia Izotova, Nitin Jain, Marina Konopleva, William G. Wierda, Elias Jabbour, Hagop M. Kantarjian, Partow Kebrieai, Emily Jones, Kara McGee, Marcela V. Maus, Matthew J. Frigault, Jami Brown, Vesselina Toncheva, Keagan S. Casey, Hanno Hock, Meaghan A McKeown, Richard Mathews and 40 more - The Lancet 2020 cited by 360

  6. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

    Authors: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Gilles Salles, William G. Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, John C. Byrd - The Lancet 2020 cited by 612

  7. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

    Authors: Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech‐Marańda, Nicole Lamanna, Constantine S. Tam, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Bita Fakhri, Chan Y. Cheah, Manish R. Patel, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna Rhodes, Francisco J. Hernandez‐Ilizaliturri, Pier Luigi Zinzani, John F. Seymour, Minna Balbas, Binoj C. Nair, Paolo Abada, Chunxiao Wang, Amy S. Ruppert, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak - New England Journal of Medicine 2023 cited by 217

  8. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

    Authors: Tanya Siddiqi, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob D. Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena Perna, Sherilyn A. Tuazon, San-San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G. Wierda - The Lancet 2023 cited by 198

  9. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

    Authors: Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Y. Cheah, John M. Pagel, Jennifer A. Woyach, Bita Fakhri, Toby A. Eyre, Nicole Lamanna, Manish R. Patel, Alvaro J. Alencar, Ewa Lech‐Marańda, William G. Wierda, Catherine C. Coombs, James N. Gerson, Paolo Ghia, Steven Le Gouill, David Lewis, Suchitra Sundaram, Jonathon B. Cohen, Ian W. Flinn, Constantine S. Tam, Minal Barve, Bryone J. Kuss, Justin Taylor, Omar Abdel‐Wahab, Stephen J. Schuster, M. Lia Palomba, Katharine L. Lewis, Lindsey E. Roeker, Matthew S. Davids, Xuan Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora Ku, Edward Y. Zhu, Jessica Chen, Ming Yin, Binoj C. Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang - The Lancet 2021 cited by 454

  10. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

    Authors: Romain Guièze, Vivian M. Liu, Daniel Rosebrock, Alexis A. Jourdain, María Hernández‐Sánchez, Aina Zurita Martinez, Jing Sun, Elisa ten Hacken, Kaitlyn Baranowski, Philip A. Thompson, Jin-Mi Heo, Zachary Cartun, Ozan Aygün, J. Bryan Iorgulescu, Wandi Zhang, Giulia Notarangelo, Dimitri Livitz, Shuqiang Li, Matthew S. Davids, Anat Biran, Stacey M. Fernandes, Jennifer R. Brown, Ana Lako, Zoe Ciantra, Matthew A. Lawlor, Derin B. Keskin, Namrata D. Udeshi, William G. Wierda, Kenneth J. Livak, Anthony Letai, Donna Neuberg, J. Wade Harper, Steven A. Carr, Federica Piccioni, Christopher J. Ott, Ignaty Leshchiner, Cory M. Johannessen, John G. Doench, Vamsi K. Mootha, Gad Getz, Catherine J. Wu - Cancer Cell 2019 cited by 360

  11. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    Authors: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien - New England Journal of Medicine 2013 cited by 2,249

  12. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

    Authors: Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer‐Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia - Blood 2022 cited by 238

  13. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

    Authors: Francesco Paolo Tambaro, Harjeet Singh, Emily Jones, Michael Rytting, Kris M. Mahadeo, Philip A. Thompson, Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Guillermo Garcia‐Manero, Tim Hon Man Chan, Rutul R. Shah, William G. Wierda - Leukemia 2021 cited by 181

  14. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

    Authors: Reuben Benjamin, Nitin Jain, Marcela V. Maus, Nicolas Boissel, Charlotte Graham, Agnieszka Jóźwik, Deborah Yallop, Marina Konopleva, Matthew J. Frigault, Takanori Teshima, Koji Kato, Floriane Boucaud, Svetlana Balandraud, Athos Gianella-Borradori, Florence Binlich, Ibtissam Marchiq, Sandra Dupouy, Maria Almena-Carrasco, Matthieu Pannaux, Sylvain Fouliard, Éolia Brissot, Mohamad Mohty, Reuben Benjamin, Charlotte Graham, Agnieszka Jóźwik, Deborah Yallop, Laarni Bonganay, Lorraine Catt, Jackie Chappell, Gary Cheung, Vicky Chu, Kirsty Cuthill, Steven Devereux, Alan Dunlop, Rose Ellard, Farzin Farzeneh, Najeem Folarin, Elka Giemza, Shireen Kassam, Majid Kazmi, Andrea Kühnl, Jen Lewis, M.Yu. Liskova, Alice Mason, Victoria Metaxa, Ghulam Mufti, Helena Munro, Antonio Pagliuca, Piers Patten, Victoria Potter, Carmel Rice, Adeel Saleem, Robin Sanderson, Orla Stewart, Elias Jabbour, Nitin Jain, Emily Jones, Hagop M. Kantarjian, Partow Kebriaei, Marina Konopleva, Kara McGee, William G. Wierda, Jami Brown, Keagan S. Casey, Matthew J. Frigault, Hanno Hock, Richard Mathews, Marcela V. Maus, Meaghan A McKeown, Thomas R. Spitzer, Vesselina Toncheva, Élie Azoulay, Nicolas Boissel, Sophie Caillat‐Zucman, Karine Celli‐Lebras, Emmanuelle Clappier, Raphaël Itzykson, Jérôme Larghero, Étienne Lengliné, Isabelle Madelaine, Martine Meunier, Florence Rabian, Emmanuel Raffoux, Marie-Thérèse Tremorin, Agnès Bonnin, Éolia Brissot, Anne Daguenel-Nguyen, Rémy Duléry, Tounes Ledraa, Florent Malard, Clémence Mediavilla, Mohamad Mohty, Anne Vekhoff, Takanori Teshima, Koji Kato - The Lancet Haematology 2022 cited by 136

  15. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

    Authors: Bijal Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen M. O’Dwyer, Houston Holmes, Martha Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae H. Park, Mehrdad Abedi, Januario E. Castro, Daniel J. DeAngelo, Adriana K. Malone, Raya Mawad, Gary J. Schiller, John M. Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K. Jain, Remus Vezan, William G. Wierda - Blood 2021 cited by 200

  16. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

    Authors: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd - Leukemia 2022 cited by 200

  17. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

    Authors: William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M. Pagel, Ian W. Flinn, Yvonne Pak, Cathy Zhou, Edith Szafer‐Glusman, Joi Ninomoto, James P. Dean, Danelle F. James, Paolo Ghia, Constantine S. Tam - Journal of Clinical Oncology 2021 cited by 229

  18. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

    Authors: Andrew W. Roberts, John F. Seymour, Jennifer R. Brown, William G. Wierda, Thomas J. Kipps, Seong Lin Khaw, Dennis Carney, Simon He, David C.S. Huang, Hao Xiong, Yue Cui, Todd Busman, Evelyn McKeegan, Andrew Krivoshik, Sari H. Enschede, Rod Humerickhouse - Journal of Clinical Oncology 2011 cited by 818

  19. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

    Authors: Partow Kebriaei, Harjeet Singh, M. Helen Huls, Matthew J. Figliola, Roland L. Bassett, Simon Olivares, Bipulendu Jena, Margaret J. Dawson, Pappanaicken R. Kumaresan, Shihuang Su, Sourindra N. Maiti, Jianliang Dai, Branden S. Moriarity, Marie-Andrée Forget, Vladimir Senyukov, Aaron Orozco, Tingting Liu, Jessica M McCarty, Rineka N. Jackson, Judy S. Moyes, Gabriela Rondón, Muzaffar H. Qazilbash, Stefan O. Ciurea, Amin M. Alousi, Yago Nieto, Katy Rezvani, David Marín, Uday Popat, Chitra Hosing, Elizabeth J. Shpall, Hagop M. Kantarjian, Michael J. Keating, William G. Wierda, Kim‐Anh Do, David A. Largaespada, Dean A. Lee, Perry B. Hackett, Richard E. Champlin, Laurence J.N. Cooper - Journal of Clinical Investigation 2016 cited by 504

  20. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Authors: Matthew S. Davids, Andrew W. Roberts, John F. Seymour, John M. Pagel, Brad S. Kahl, William G. Wierda, Soham D. Puvvada, Thomas J. Kipps, Mary Ann Anderson, Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Franklin Peale, Jeremy A. Ross, Lori A. Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod Humerickhouse, Gary Gordon, John F. Gerecitano - Journal of Clinical Oncology 2017 cited by 751

  21. Ibrutinib and Venetoclax for First-Line Treatment of CLL

    Authors: Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev Estrov, Nathan Fowler, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yılmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias Jabbour, Koji Sasaki, Rashmi Kanagal‐Shamanna, Keyur P. Patel, Jeffrey L. Jorgensen, Naveen Garg, Xuemei Wang, Katrina Sondermann, Nichole Cruz, Chongjuan Wei, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda - New England Journal of Medicine 2019 cited by 504

  22. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

    Authors: Elias Jabbour, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Xuelin Huang, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, William G. Wierda, Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, Koji Sasaki, Tapan M. Kadia, Joseph D. Khoury, Sa A. Wang, Fadi Haddad, Jovitta Jacob, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian - The Lancet Haematology 2023 cited by 103

  23. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    Authors: John C. Byrd, Bonnie K. Harrington, Susan O’Brien, Jeffrey A. Jones, Anna Schuh, Steve Devereux, Jorge Chaves, William G. Wierda, Farrukh T. Awan, Jennifer R. Brown, Peter Hillmen, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, John M. Pagel, Jennifer A. Woyach, Dave Johnson, Jane Huang, Xiaolin Wang, Allard Kaptein, Brian J. Lannutti, Todd Covey, Maria Fardis, Jesse McGreivy, Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Thomas G. Diacovo, Amy J. Johnson, Richard R. Furman - New England Journal of Medicine 2015 cited by 891

  24. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Authors: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutré, John F. Seymour, Talha Munir, Soham D. Puvvada, Clemens‐Martin Wendtner, Andrew W. Roberts, Wojciech Jurczak, Stephen P. Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari H. Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G. Wierda - The Lancet Oncology 2016 cited by 796